Our findings that MI-2 administration prevents MALT1-mediated MCPIP1 degradation in vivo and protects mice from LPS-induced inflammation and lung injury, suggests that pharmacological inhibition of MALT1 protease activity by MI-2 may be an effective strategy for preventing/treating sepsis-associated lung injury. Here, ZC3H12A is linked to Sepsis.